#United States #Boston #Haemonetics #GVS #blood collection

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

On January 14, 2025, Haemonetics Corporation (NYSE: HAE), a prominent medical technology firm, announced that it has successfully concluded the sale of its whole blood assets to GVS, S.p.A, a leading producer of filtration solutions for healthcare and life sciences.

Transaction Overview

The deal primarily involves GVS acquiring Haemonetics' exclusive range of whole blood collection, processing, and filtration technologies. This includes vital assets such as the production facility located in Covina, California, and manufacturing equipment situated in Tijuana, Mexico. The total monetary consideration for this transaction can reach up to $67.8 million, which comprises $45.3 million payable upfront along with a potential $22.5 million in contingent earn-outs over the next four years based on performance metrics.

Haemonetics plans to allocate the proceeds from this transaction toward general corporate purposes and additional investment in growth strategies. This decision reflects the company's commitment to enhancing its product offerings and continuing to innovate in the medical sector.

Future Plans for Haemonetics

Post-transaction, Haemonetics remains focused on its Blood Center operations, which will continue providing customers with its complete range of apheresis solutions. The company's offerings include advanced devices and disposable kits that support various apheresis collections—such as platelets, plasma, and red cells—ensuring smoothing operations within blood centers.

The upcoming third-quarter earnings call, set for February 6, 2025, will provide detailed insights regarding the financial implications of this transaction on Haemonetics' fiscal outlook. Stakeholders and analysts are eagerly anticipating how the company’s growth initiatives will unfold going forward, especially in light of this strategic asset divestiture.

About Haemonetics

Founded with the goal of optimizing patient outcomes through innovative medical solutions, Haemonetics Corporation is dedicated to advancing healthcare technologies. The company specializes in several critical areas, including blood and plasma component collection, surgical services, and transfusion therapies. For more information, visit Haemonetics.

Conclusion

Haemonetics' asset sale to GVS marks a pivotal moment for both companies, potentially enabling GVS to strengthen its footprint in the healthcare sector while allowing Haemonetics to refocus resources on its growth and innovation strategies. Stakeholder scrutiny will remain high as the impacts of this transaction begin to unfold in the coming fiscal periods.